Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine

International Journal of Obesity

Volumn 25, Issue 10, 2001, Pages 1450-1453

  Prow, M R ^a   Lancashire, B ^a   Aspley, S ^a   Heal, D J ^a   Kilpatrick, I C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

5HT release; Anterior hypothalamus; Dexfenfluramine; In vitro; In vivo; Phentermine

Indexed keywords

ANTIOBESITY AGENT; CATECHOLAMINE; DEXFENFLURAMINE; PHENTERMINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; BRAIN TISSUE; CONTROLLED STUDY; DRUG POTENTIATION; HYPOTHALAMUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

ANIMALS; DEXFENFLURAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HYPOTHALAMUS, ANTERIOR; MALE; MICRODIALYSIS; PHENTERMINE; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN ANTAGONISTS;

ANIMALIA;

EID: 0034779888     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801717     Document Type: Article

References (26)

1. Obesity. Present and future pharmacological approaches
2. The effect of selective lesioning of brain catecholamine-containing neurons on the activity of various anorectics in the rat
3. The pharmacologic approach to the treatment of obesity
4. Update on the pharmacotherapy of obesity
5. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents; sibutramine is a reuptake inhibitor
6. Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-amphetamine and d-fenfluramine
7. Long-term weight control: The National Heart, Lung, and Blood Institute funded multimodel intervention study
8. Obesity drugs and the heart
9. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
10. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography
11. 2B receptors in the cardiopathy associated with fenfluramine
12. A comparison of the effects on central 5HT function of sibutramine hydrochloride and other weight-modifying agents
13. Behavioral and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats
14. Aminorex, fenfluramine, and chlorphentermine and serotonin transporter substrates. Implications for primary pulmonary hypertension
15. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications
16. Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: In vivo microdialysis study in conscious animals
17. Monoamine release and uptake inhibition profiles of antiobesity agents
18. Characterization of monoamine release in the lateral hypothalamus of awake, freely moving rats using in vivo microdialysis
19. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat
20. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors
21. Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: A comparison with their abilities to evoke monoamine release
22. Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets
23. d-Fenfluramine releases 5HT from whole blood of rats as measured by in vitro microdialysis
24. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue
25. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin
26. Hypothalamic serotonin: Pharmacological, biochemical, and behavioural analyses of its feeding-suppressive action